Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer

被引：0
|
作者：
Shtivelband, Mikhail
Spigel, David R.
Gerber, David E.
Jain, Minish Mahendra
Ponomarova, Olga V.
Giorgadze, Davit
Shan, Joseph
Menander, Kerstin B.
Belani, Chandra Prakash
机构：
[1] Ironwood Canc & Res Ctr, Chandler, AZ USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] UT Southwestern Med Ctr, Dallas, TX USA
[4] Ruby Hall Clin, Pune, Maharashtra, India
[5] RE Kavetsky Inst Expt Pathol Oncol & Radiobiol, Kiev, Ukraine
[6] Chemotherapy & Immunotherapy Clin, Tbilisi, Georgia
[7] Peregrine Pharmaceut Inc, Tustin, CA USA
[8] Penn State Hershey Canc Inst, Hershey, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8095
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical benefits of sequential administration of docetaxel and intermittent erlotinib as a second-line therapy for advanced non-small cell lung cancer (NSCLC): A phase II randomized study
    Aparisi, Francisco
    Sanchez-Hernandez, Alfredo
    Giner, Vicente
    Munoz-Langa, Jose
    Esquerdo, Gaspar
    Lopez Jimenez, Antonio
    Garde, Javier
    Garcia Sanchez, Jose
    Juan Vidal, Oscar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] CLINICAL BENEFITS OF SEQUENTIAL ADMINISTRATION OF DOCETAXEL AND INTERMITTENT ERLOTINIB AS A SECOND-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC), A PHASE II RANDOMIZED STUDY
    Juan Vidal, Oscar
    Garcia Sanchez, Jose
    Sanchez, Alfredo
    Giner, Vicente
    Munoz Langa, Jose
    Esquerdo, Gaspar
    Lopez, Antonio
    Garde, Javier
    de Asis Aparisi, Francisco
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1177 - S1178
  • [43] Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer
    Ceresoli, GL
    Gregorc, V
    Cordio, S
    Bencardino, KB
    Schipani, S
    Cozzarini, C
    Bordonaro, R
    Villa, E
    LUNG CANCER, 2004, 44 (02) : 231 - 239
  • [44] A Randomized Phase 3 Study of Camrelizumab plus Chemotherapy as 1st Line Therapy for Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Zhou, C.
    Chen, G.
    Huang, Y.
    Zhou, J.
    Lin, L.
    Feng, J.
    Wang, Z.
    Shu, Y.
    Shi, J.
    Hu, Y.
    Wang, Q.
    Cheng, Y.
    Chen, J.
    Lin, X.
    Wang, Y.
    Huang, J.
    Cui, J.
    Cao, L.
    Liu, Y.
    Zhang, Y.
    Pan, Y.
    Zhao, J.
    Wang, L.
    Chang, J.
    Chen, Q.
    Ren, X.
    Zhang, W.
    Fan, Y.
    He, Z.
    Fang, J.
    Gu, K.
    Dong, X.
    Jin, F.
    Gao, H.
    An, G.
    Ding, C.
    Jiang, X.
    Xiong, J.
    Zhou, X.
    Hu, S.
    Lu, P.
    Liu, A.
    Guo, S.
    Huang, J.
    Zhu, C.
    Zhao, J.
    Gao, B.
    Chen, Y.
    Hu, C.
    Zhang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S215 - S216
  • [45] Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer
    Ready, Neal
    Karaseva, Nina A.
    Orlov, Sergey V.
    Luft, Alexander V.
    Popovych, Olexandr
    Holmlund, Jon T.
    Wood, Brian A.
    Leopold, Lance
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (04) : 781 - 785
  • [46] Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer
    Pesek, M
    Holá, V
    LUNG CANCER: CURRENT TOPICS, 2001, : 155 - 160
  • [47] Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer
    Eager, R. M.
    Cunningham, C. C.
    Senzer, N.
    Richards, D. A.
    Raju, R. N.
    Jones, B.
    Uprichard, M.
    Nemunaitis, J.
    CLINICAL ONCOLOGY, 2009, 21 (06) : 464 - 472
  • [48] A randomized Phase II trial of docetaxel alone and in combination with gefitinib (IRESSA) as second-line therapy for patients with non-small-cell lung cancer
    Robinet, G
    Falchero, L
    Perol, M
    Thomas, P
    Monnet, I
    Grivaux, M
    Crequit, J
    Letreut, J
    Paillotin, D
    Chouaid, C
    LUNG CANCER, 2005, 49 : S33 - S33
  • [49] A randomized placebo-controlled clinical study of nab-paclitaxel as second-line chemotherapy for patients with advanced non-small cell lung cancer in China
    Wu, Yueming
    Feng, Jiang
    Hu, Weiwei
    Luo, Qingquan
    BIOSCIENCE REPORTS, 2017, 37
  • [50] A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Jones, Suzanne
    Thompson, Dana
    Barton, John
    Patton, Jeff
    Shipley, Dianna
    Greco, E. Anthony
    Spigel, David
    Infante, Jeff
    Burris, Howard A., III
    CLINICAL LUNG CANCER, 2008, 9 (03) : 154 - 159
12345